We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+41.78%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$1.39B
AUM Growth
+$336M
Cap. Flow
+$96.4M
Cap. Flow %
6.95%
Top 10 Hldgs %
75.78%
Holding
46
New
8
Increased
24
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$50.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$27.4M
3
LIVN icon
LivaNova
LIVN
+$26.4M
4
QGEN icon
Qiagen
QGEN
+$18.4M
5
ILMN icon
Illumina
ILMN
+$13M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$29.2M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$22.1M
3
EW icon
Edwards Lifesciences
EW
+$20.3M
4
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$14M
5
BMY icon
Bristol-Myers Squibb
BMY
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ECOR icon
26
electroCore
ECOR
$54.8M
$8.34M 0.6%
+33,700
New +$9.16M
NVTR
27
DELISTED
Nuvectra Corporation Common Stock
NVTR
$7.86M 0.57%
383,030
-124,031
-24% -$2.09M
VIVE
28
DELISTED
VIVEVE MED INC
VIVE
$7.78M 0.56%
2,861
+303
+12% +$873K
ODT
29
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$6.1M 0.44%
276,368
+1,824
+0.7% +$42.5K
STIM icon
30
Neuronetics
STIM
$138M
$5.06M 0.36%
+190,000
New +$5.17M
QTTB icon
31
Q32 Bio
QTTB
$466M
$4.62M 0.33%
12,580
+80
+0.6% +$28.6K
NVAX icon
32
Novavax
NVAX
$1.2B
$3.54M 0.26%
132,217
-4,108
-3% -$139K
KA
33
DELISTED
Kineta, Inc. Common Stock
KA
$3.01M 0.22%
7,696
-196
-2% -$123K
ARGX icon
34
argenx
ARGX
$53.4B
$2.12M 0.15%
25,559
+102
+0.4% +$9.12K
ELDN icon
35
Eledon Pharmaceuticals
ELDN
$261M
$2.11M 0.15%
16,767
+100
+0.6% +$10.3K
MRKR icon
36
Marker Therapeutics
MRKR
$18.8M
$1.89M 0.14%
+20,000
New +$1.02M
BLCM
37
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.11M 0.08%
+15,029
New +$1.17M
ADVM
38
DELISTED
Adverum Biotechnologies
ADVM
$935K 0.07%
17,637
+116
+0.7% +$6.98K
MOTS
39
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$428K 0.03%
198
-197
-50% -$306K
EW icon
40
Edwards Lifesciences
EW
$49.6B
– –
-435,738
Closed -$20.3M
OSUR icon
41
OraSure Technologies
OSUR
$279M
– –
-117,291
Closed -$1.98M
GBT
42
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-456,921
Closed -$22.1M
ARMO
43
DELISTED
ARMO BioSciences, Inc. Common Stock
ARMO
– –
-413,892
Closed -$14M
AVXS
44
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-236,425
Closed -$29.2M
1
2

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $9.92B AUM 21.52% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

RTW Investments's Q2 2018 Portfolio in Review

As of Q2 2018, RTW Investments held 46 positions worth $1.39B, up 32% from $1.05B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

RTW Investments deployed $96.4M of net new capital in Q2 2018, opening 8 new positions and adding to 24 existing holdings. Its largest new stake was Qiagen: 499,239 shares worth $19.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $10.4M trimmed.

  • RTW Investments's largest Q2 2018 buy was Qiagen: 499,239 shares worth $19.1M.
  • RTW Investments added most to Arrowhead Research in Q2 2018, an estimated $50.3M increase.
  • RTW Investments's biggest Q2 2018 reduction was Bristol-Myers Squibb, cutting an estimated $10.4M.
  • RTW Investments fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $29.2M.
  • RTW Investments's ten largest holdings make up 76% of its $1.39B portfolio in Q2 2018.
  • RTW Investments opened 8 new positions and closed 6 in Q2 2018.
  • RTW Investments's portfolio value rose 32% quarter-over-quarter to $1.39B.

Based on RTW Investments's 13F filing for Q2 2018, filed 14 Aug 2018.